AI Article Synopsis
- - The study by Hirschfield et al. showed that the PPARδ agonist seladelpar is safe and has meaningful effectiveness for patients with primary biliary cholangitis.
- - Seladelpar could serve as a second-line treatment option to help reduce disease activity in these patients.
- - The drug also has the potential to alleviate pruritus, which is a common and uncomfortable symptom of the condition.
Article Abstract
The study by Hirschfield et al. demonstrated safety profile and clinically significant effectiveness of the peroxisome proliferator-activated receptor delta (PPARδ) agonist seladelpar in patients with primary biliary cholangitis, highlighting its plausible use as a second-line treatment to reduce disease activity and pruritus.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.medj.2024.03.019 | DOI Listing |
Publication Analysis
Top Keywords
patients primary
8
primary biliary
8
biliary cholangitis
8
seladelpar hope
4
hope patients
4
cholangitis study
4
study hirschfield
4
hirschfield et al
4
et al demonstrated
4
demonstrated safety
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!